INFI
  
  
      
        Infinity Pharmaceuticals, Inc.
      
      
        
          INFI
        
        
      
    
  
          INFI
        
        
      Delisted
    INFI was delisted on the 13th of September, 2023.
64 hedge funds and large institutions have $36.3M invested in Infinity Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 14 closing their positions.
New
  Increased
  Maintained
  Reduced
  Closed
  more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
55% less capital invested
Capital invested by funds: $80.2M → $36.3M (-$43.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
    
      Holders
    
  
  
    
      
        
      
        64
      
    
      
    
  
    
      Holding in Top 10
    
  
  
    
      
        
      
        –
      
    
      
    
  
    
      Calls
    
  
  
    
      
        
      
        $211K
      
    
      
    
  
    
      Puts
    
  
  
    
      
        
      
        $22K
      
    
      
    
  
Top Buyers
| 1 | +$2.59M | |
| 2 | +$525K | |
| 3 | +$346K | |
| 4 | 
          
   
    PIM
   
  
      Platinum Investment Management
     
    
      
        Sydney Australia 2000,
      
      
        Australia
      
     
   | 
        +$173K | 
| 5 | 
          
   
      Acadian Asset Management
     
    
      
        Boston,
      
      
        Massachusetts
      
     
   | 
        +$151K | 
Top Sellers
| 1 | -$1.43M | |
| 2 | -$1.25M | |
| 3 | -$988K | |
| 4 | 
          
   
    GCP
   
  
      GSA Capital Partners
     
    
      
        London,
      
      
        United Kingdom
      
     
   | 
        -$771K | 
| 5 | 
          
   
    OM
   
  
      Opaleye Management
     
    
      
        Boston,
      
      
        Massachusetts
      
     
   | 
        -$745K |